Sponsor: Johnson and Johnson - J&J
Sponsor Study ID: COPERNICUS (61186372NSC2012)
Study Title: A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
CTO #: 104164
NCT Number: NCT06667076
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lung
Study Objectives: The primary objective of this study is to assess the antitumor activity of amivantamab SC and Lazertinib (Cohort 1), and amivantamab SC and chemotherapy (Cohort 2) in participants with EGFRm NSCLC.